NASDAQ:MEDP - Medpace Stock Price, Price Target & More

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings (NASDAQ:MEDP) issued its earnings results on Monday, April, 30th. The company reported $0.60 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.43 by $0.17. The firm had revenue of $108.40 million for the quarter, compared to the consensus estimate of $113.12 million. Medpace had a return on equity of 12.50% and a net margin of 10.37%. The company's revenue was up 15.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.34 EPS. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Medpace.

Medpace updated its FY18 earnings guidance on Monday, April, 30th. The company provided earnings per share (EPS) guidance of $1.87-1.97 for the period, compared to the Thomson Reuters consensus estimate of $1.88. The company issued revenue guidance of $421-435 million, compared to the consensus revenue estimate of $463.04 million.

8 equities research analysts have issued twelve-month price targets for Medpace's stock. Their predictions range from $35.00 to $42.00. On average, they expect Medpace's share price to reach $37.40 in the next year. View Analyst Ratings for Medpace.

Medpace saw a drop in short interest in May. As of May 15th, there was short interest totalling 267,456 shares, a drop of 47.9% from the April 30th total of 512,869 shares. Based on an average daily volume of 536,998 shares, the days-to-cover ratio is presently 0.5 days. Currently, 2.3% of the shares of the stock are sold short.

Some companies that are related to Medpace include PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), Viralytics (VRACY), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA) and Senomyx (SNMX).

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Media stories about MEDP stock have been trending somewhat negative on Sunday, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Medpace earned a media sentiment score of -0.02 on Accern's scale. They also gave news headlines about the company an impact score of 47.35 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Medpace's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include CINVEN CAPITAL MANAGEMENT (V) GENERAL PARTNER LTD (37.70%), BlackRock Inc. (3.42%), Bernzott Capital Advisors (1.95%), UBS Group AG (0.91%), Granite Investment Partners LLC (0.73%) and Prudential Financial Inc. (0.50%). Company insiders that own Medpace stock include August J Troendle, Medpace Limited Partnership and Susan E Burwig. View Institutional Ownership Trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Alambic Investment Management L.P., Hsbc Holdings PLC, Federated Investors Inc. PA, Granite Investment Partners LLC, Thrivent Financial for Lutherans, Bernzott Capital Advisors and Wells Fargo & Company MN. View Insider Buying and Selling for Medpace.

MEDP stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Dimensional Fund Advisors LP, American Century Companies Inc., Prudential Financial Inc., BlackRock Inc., Russell Investments Group Ltd., Allianz Asset Management GmbH and Allianz Asset Management GmbH. Company insiders that have bought Medpace stock in the last two years include August J Troendle and Susan E Burwig. View Insider Buying and Selling for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $42.00.

Medpace has a market capitalization of $1.49 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]